New immune drug PHST001 enters first human trials for Hard-to-Treat cancers

NCT ID NCT06840886

Recruiting now Disease control Sponsor: Pheast Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (including ovarian, endometrial, and bile duct cancers) that have not responded to other treatments. The main goals are to check safety and find the best dose.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PHST001 (an experimental immune therapy that targets CD24 on cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced solid tumors that have stopped responding to standard therapies.
What could go wrong: This is a very early (Phase 1) trial, so the main goal is safety, not effectiveness. It may not shrink tumors or improve survival, and there could be unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

central nervous system cancer central nervous system neoplasm cholangiocarcinoma endometrial cancer endometrium neoplasm neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS CHOLANGIOCARCINOMA CNS TUMOR ENDOMETRIAL CANCER OVARIAN CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Dana Farber Cancer Institute
RECRUITING

Boston, Massachusetts, 02215, United States
Duke Cancer Institute
RECRUITING

Durham, North Carolina, 27710, United States
MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Mount Sinai
RECRUITING

New York, New York, 10029, United States
NEXT Oncology - Dallas
RECRUITING

Irving, Texas, 75039, United States
NEXT Oncology - Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
Precision NextGen Oncology & Research Center
RECRUITING

Beverly Hills, California, 90212, United States
START Center for Cancer Research - Long Island New York
RECRUITING

Lake Success, New York, 11042, United States
START Center for Cancer Research - Midwest
RECRUITING

Grand Rapids, Michigan, 49546, United States
START Center for Cancer Research - Texas
RECRUITING

Fort Worth, Texas, 76104, United States
Sarah Cannon Research Institute (SCRI) Oncology Partners
RECRUITING

Nashville, Tennessee, 37203, United States
Sarah Cannon Research Institute (SCRI) Oncology Partners - Denver Health One
RECRUITING

Denver, Colorado, 80218, United States
South Texas Accelerated Research Therapeutics (START)
RECRUITING

San Antonio, Texas, 78229, United States
Stanford University School of Medicine
RECRUITING

Palo Alto, California, 94304, United States
USC Norris Comprehensive Cancer Center
RECRUITING

Los Angeles, California, 90033, United States
University of Chicago Medical Center
RECRUITING

Chicago, Illinois, 60637, United States
University of Michigan Rogel Cancer Center
RECRUITING

Ann Arbor, Michigan, 48109, United States
University of Texas (UT) Health
RECRUITING

San Antonio, Texas, 78229, United States
Vanderbilt-Ingram Cancer Center
RECRUITING

Nashville, Tennessee, 37203, United States
Yale Cancer Center
RECRUITING

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.